重组抗EGFR人鼠嵌合单抗联合伊立替康治疗伊立替康难治性结肠癌1例(2)
[参考文献]
[1] Boyle P，Ferlay J. Mortality and survial in breast and colorectal cancer [J]. Nat Clin Pract Oncol，2005，2(9)：424-425.
[2] Kawaguchi Y，Kono K，Mimura K，et al. Cetuximab induce antibody dependent cellular cytotoxicity against EGFR-expressing esophageal squamous cell carcinoma [J]. Int J Cancer，2006，120(4)：781-787.
[3] Cunningham D，Humblet Y，Siena S，et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer [J]. N Engl J Med，2004，351(4)：337-345.
[4] Tsuchida Y，Therasse P. Response evaluation criteria in solid tumors (RECIST)：new guidelines [J]. Med Pediatr Onco，2001，37(1)：1-3.
[5] Alberto F，Sobrero JM，Louis F，et al. EPIC：phase Ⅲ trail of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer [J]. J Clin Oncol，2008，26(14)：2311-2319.
[6] Van CE，Nowacki M，Lang I，et al. Randomized phase Ⅲ study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer(mCRC)：the CRYSTAL trail [J]. J Clin Oncol，2007，25(18)：4000.
[7] Van CE，Lang I，Folprecht G，et al. Cetuximab plus FOLFIRI：final data from the CRYSTAL study on the association of KRAS and BRAF biomarker status with treatment outcome [J]. J Clin Oncol，2010，28(15)：3570.
(收稿日期：2012-02-27 本文编辑：张瑜杰), 百拇医药(王瑾)
[1] Boyle P，Ferlay J. Mortality and survial in breast and colorectal cancer [J]. Nat Clin Pract Oncol，2005，2(9)：424-425.
[2] Kawaguchi Y，Kono K，Mimura K，et al. Cetuximab induce antibody dependent cellular cytotoxicity against EGFR-expressing esophageal squamous cell carcinoma [J]. Int J Cancer，2006，120(4)：781-787.
[3] Cunningham D，Humblet Y，Siena S，et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer [J]. N Engl J Med，2004，351(4)：337-345.
[4] Tsuchida Y，Therasse P. Response evaluation criteria in solid tumors (RECIST)：new guidelines [J]. Med Pediatr Onco，2001，37(1)：1-3.
[5] Alberto F，Sobrero JM，Louis F，et al. EPIC：phase Ⅲ trail of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer [J]. J Clin Oncol，2008，26(14)：2311-2319.
[6] Van CE，Nowacki M，Lang I，et al. Randomized phase Ⅲ study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer(mCRC)：the CRYSTAL trail [J]. J Clin Oncol，2007，25(18)：4000.
[7] Van CE，Lang I，Folprecht G，et al. Cetuximab plus FOLFIRI：final data from the CRYSTAL study on the association of KRAS and BRAF biomarker status with treatment outcome [J]. J Clin Oncol，2010，28(15)：3570.
(收稿日期：2012-02-27 本文编辑：张瑜杰), 百拇医药(王瑾)